CogState Ltd

23 articles about CogState Ltd

• Clario and Cogstate Expand Partnership to Deliver Leading Data Collection and Data Quality Programs for Neuroscience Clinical Trials

  5/20/2022

  Collaboration combines Clario's eCOA innovations with Cogstate's expertise in neuroscience research to yield highest quality endpoints.

• Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies

  10/26/2020

  Eisai Co., Ltd. and Cogstate, Ltd. announced that the companies have entered into a collaboration whereby Eisai has secured the global development rights and exclusive commercialization rights of all cognitive function tests developed by Cogstate, including the "Cogstate Brief BatteryTM" for use in healthcare and other markets.

• OTC Markets Group Welcomes Cogstate Ltd. to OTCQX

  9/9/2020

  OTC Markets Group Inc., operator of financial markets for 11,000 U.S. and global securities, announced Cogstate Ltd., a cognitive science and technology company publicly listed on the Australian Securities Exchange, has qualified to trade on the OTCQX® Best Market. Cogstate Ltd. upgraded to OTCQX from the Pink® market.

• Cogstate Announces European Approval for Healthcare Offering

  6/4/2018

  Cogstate announced that its Healthcare Division has received CE Mark approval for its CognigramTM digital cognitive assessment system.

• International Publications Validate Cogstate Technology’s Clinical Value in Detecting Postoperative Cognitive Dysfunction (POCD)

  2/13/2018

  From the Interdisciplinary Conference on Orthopedic Value Based Care sponsored by the American College of Perioperative Medicine, Cogstate announced that the Cogstate Brief Battery has now been shown to be useful for guiding decision making about cognitive outcomes in older adults awaiting or undergoing surgery.

• Cogstate Strengthens Global Clinical Science Expertise with the Appointment of Senior Vice President, Dr. Chris Edgar

  2/9/2018

  Dr. Edgar joins the Cogstate team in Europe as an experienced leader in cognitive assessment and clinical endpoint strategy.

• CogState Ltd Announces First U.S. Deployment Of The Cognigram System At University of Notre Dame

  10/11/2017

• CogState Ltd Receives Positive FDA Notification Regarding Medical Device Regulatory Submission

  7/27/2017

• CogState Ltd Selected As Preferred Provider To Eli Lilly’s Alzheimer’s Disease Platform

  5/17/2017

• CogState Ltd Strengthens Executive Team With Appointment Of Chief Technology Officer

  3/17/2017

• CogState Ltd Announces New Executive Appointments For Clinical Trials And Healthcare Business Units

  11/29/2016

• CogState Ltd And Clinical Ink Deliver Enhanced Tablet-Based eCOA For CNS Clinical Trials

  10/25/2016

• CogState Ltd IPad Cognitive Assessments Selected For Use In Phase IV Observational Study Of Approved Treatments For Prostate Cancer

  11/18/2015

• CogState Ltd Releases Latest Version Of Online Cognitive Screening Solution For Clinical Trials: Precision Recruitment

  7/22/2015

• CogState Ltd Release: Computerized Cognition Test Provides Better Assessment than Observation

  8/25/2014

• CogState Ltd Release: Early Detection Of Alzheimer's Disease Enables Caregivers To Significantly Delay Admission Of Their Loved Ones To Nursing Homes

  4/9/2014

• CogState Ltd's Technology Chosen For Major Phase 3 Trial Of Alzheimer's Disease Drug

  3/25/2014

• US Strategic Investors Commit A$3.5 Million To Drive Global Business Growth For CogState Ltd

  11/19/2013

• CogState Ltd and Merck & Co., Inc. Launch COGNIGRAM™ to Physicians in Canada

  3/6/2013

• CogState Ltd Signs Licensing Deal With Merck Canada

  6/25/2012